NET

The norepinephrine transporter (NET) is a protein embedded in the membrane of neurons that releases norepinephrine. Its job is to pull norepinephrine back out of the synaptic cleft and into the releasing cell after it has carried a signal — a process called reuptake.

NET belongs to the same family of transporters as SERT (for serotonin) and DAT (for dopamine). All three act as molecular brakes, limiting how long a neurotransmitter stays active in the synapse. NET is found most densely in the brain regions and peripheral nervous system tissues where norepinephrine signalling is heaviest: the locus coeruleus, prefrontal cortex, and sympathetic nerve terminals throughout the body.

Because it sits at a chokepoint in norepinephrine signalling, NET is a target for a range of psychoactive and therapeutic drugs.

How it works · its role

NET works by binding norepinephrine and co-transporting sodium and chloride ions across the cell membrane, using the ion gradient as a kind of molecular engine to carry the neurotransmitter back inside the neuron.

When a drug blocks NET, norepinephrine cannot be cleared and accumulates in the synapse, prolonging and amplifying its effects on postsynaptic receptors. Some drugs go further: amphetamines and related compounds enter the neuron via NET and trigger it to run in reverse, actively pumping norepinephrine out rather than in. This reversal produces a much larger and more abrupt surge than simple reuptake inhibitor alone.

The downstream effects depend on which receptors the extra norepinephrine reaches — adrenergic receptors in the brain influence alertness, attention, and stress responses, while those in the peripheral nervous system affect heart rate, blood pressure, and vasoconstriction.

Relevance to substances & effects

NET blockade is central to the action of stimulants and several antidepressant classes. Cocaine blocks NET (alongside DAT and SERT simultaneously), contributing to the cardiovascular and arousal effects that accompany its dopaminergic high.

Amphetamines are particularly potent NET substrates: by reversing the transporter they drive norepinephrine release, producing strong increases in alertness, focus, and sympathetic activation — elevated heart rate, reduced appetite, raised blood pressure. This noradrenergic action is thought to underlie much of their therapeutic usefulness in attention disorders.

SNRIs (serotonin-norepinephrine reuptake inhibitors) such as venlafaxine and duloxetine block both SERT and NET, and their NET activity is associated with analgesic effects and improvements in energy and concentration. Older tricyclic antidepressants also inhibit NET to varying degrees, alongside a broader mix of receptor targets that accounts for their side-effect profile.

Atomoxetine is a selective NET inhibitor — it blocks NET with little effect on other transporters — which illustrates how norepinephrine reuptake inhibition alone can sharpen attention without the dopaminergic reinforcement that characterises amphetamines.

Subjectively, strong NET activity tends to manifest as heightened arousal and focus, reduced fatigue, and a sense of urgency or drive — alongside the physiological signs of sympathetic activation that accompany it.